Ethinylestradiol/levonorgestrel (ascending/constant dose) - Teva

Drug Profile

Ethinylestradiol/levonorgestrel (ascending/constant dose) - Teva

Alternative Names: DR 1031; DR-0131; Levonorgestrel/ethinyl estradiol and ethinyl estradiol; Levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets; Quartette

Latest Information Update: 06 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class Alkylated estrogenic steroids; Contraceptives; Hormonal replacements; Norpregnanes; Norpregnatrienes; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 10 Feb 2014 Teva has patent protection for ethinylestradiol/levonorgestrel (ascending/constant dose) in USA
  • 24 Sep 2013 Launched for Contraception/Pregnancy (Prevention) in USA (PO) - First global launch
  • 29 Mar 2013 Registered for Contraception/Pregnancy (Prevention) in USA (PO) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top